Leypoldt J K, Charney D I, Cheung A K, Naprestek C L, Akin B H, Shockley T R
Research Service, Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
Kidney Int. 1995 Dec;48(6):1959-66. doi: 10.1038/ki.1995.497.
Low sodium peritoneal dialysate has been reported to enhance sodium loss and alleviate signs of fluid overload in continuous ambulatory peritoneal dialysis patients. To elucidate the mechanisms involved, we compared ultrafiltration and solute kinetics using low sodium dialysate (LNaD; 105 mEq/liter sodium, 2.5% glucose, 348 mOsm/liter), conventional dialysate with equal osmolality (CD1.5; 132 mEq/liter sodium, 1.5% glucose, 348 mOsm/liter) and conventional dialysate with equal glucose concentration (CD2.5; 132 mEq/liter sodium, 2.5% glucose, 403 mOsm/liter). A 2 liter, six hour exchange of each dialysate was performed on separate days in 10 chronic peritoneal dialysis patients. Transperitoneal solute diffusion was assessed by calculating the permeability-area product (PA) of the peritoneal membrane from the dependence of plasma and dialysate solute concentrations on tie. Net fluid removed using LNaD of 190 +/- 90 (SEM) ml was similar to that using CD2.5 (250 +/- 90 ml) but higher (P < 0.01) than that using CD1.5 (-200 +/- 60 ml). Sodium loss was higher using LNaD (72 +/- 11 mEq, P < 0.01) and CD2.5 (41 +/- 12 mEq, P < 0.05) than using CD1.5 (-18 +/- 8 mEq). Changes in plasma sodium concentration were small during each dwell and were not different among the study dialysates. PA values for urea (23.4 +/- 1.6 ml/min), creatinine (10.0 +/- 1.0 ml/min), and glucose (10.3 +/- 1.3 ml/min) were similar when determined in each dialysate. The PA value for sodium (7.6 +/- 1.5 ml/min) could only be accurately determined in LNaD. We conclude that: (1) net fluid removed is greater using LNaD than CD1.5 despite similar osmolalities because LNaD has a higher glucose concentration and glucose is a more effective osmotic solute than sodium; (2) sodium loss when using LNaD is enhanced by both diffusion and convection; and (3) sodium diffuses across the peritoneum slower than urea, creatinine and glucose. These data suggest that LNaD alleviates signs of fluid overload by increasing net fluid removal and enhancing sodium loss.
据报道,低钠腹膜透析液可增加钠的丢失,并减轻持续性非卧床腹膜透析患者的液体超负荷症状。为阐明其中的机制,我们比较了使用低钠透析液(LNaD;钠浓度105 mEq/升,葡萄糖2.5%,渗透压348 mOsm/升)、等渗常规透析液(CD1.5;钠浓度132 mEq/升,葡萄糖1.5%,渗透压348 mOsm/升)和等葡萄糖浓度常规透析液(CD2.5;钠浓度132 mEq/升,葡萄糖2.5%,渗透压403 mOsm/升)时的超滤和溶质动力学情况。对10例慢性腹膜透析患者在不同日期分别进行了每次2升、持续6小时的每种透析液交换。通过根据血浆和透析液溶质浓度随时间的变化关系计算腹膜的通透面积乘积(PA)来评估经腹膜溶质扩散情况。使用LNaD清除的净液体量为190±90(SEM)毫升,与使用CD2.5(250±90毫升)时相似,但高于使用CD1.5(-200±60毫升)时(P<0.01)。使用LNaD(72±11 mEq,P<0.01)和CD2.5(41±12 mEq,P<0.05)时的钠丢失高于使用CD1.5(-18±8 mEq)时。每次留存期间血浆钠浓度变化较小,且各研究透析液之间无差异。在每种透析液中测定时,尿素(23.4±1.6毫升/分钟)、肌酐(10.0±1.0毫升/分钟)和葡萄糖(10.3±1.3毫升/分钟)的PA值相似。仅在LNaD中能准确测定钠的PA值(7.6±1.5毫升/分钟)。我们得出结论:(1)尽管渗透压相似,但使用LNaD清除的净液体量比CD1.5多,因为LNaD的葡萄糖浓度更高,且葡萄糖是比钠更有效的渗透溶质;(2)使用LNaD时钠的丢失通过扩散和对流均增加;(3)钠跨腹膜的扩散比尿素、肌酐和葡萄糖慢。这些数据表明,LNaD通过增加净液体清除和增强钠丢失来减轻液体超负荷症状。